Pinsent Masons expands Life Sciences Group with team hire

18 Feb 2013 | 09:15 am | 1 min. read

International law firm Pinsent Masons has boosted its Life Sciences group with the appointment of a four-strong Partner team.

The team of Paul Ranson, Allistair Booth, Stuart Richards and Charles Waddell - has a market-leading reputation for life sciences IP, regulatory and transactional work. 

They join a formidable Life Sciences team at Pinsent Masons, led by life sciences patent litigator Clare Tunstall, and complete the firm's full-service offering across the sector. 

Paul Ranson is a well-known figure in the Life Sciences world having previously headed the Healthcare group at Simmons & Simmons.

Allistair Booth and Stuart Richards work across corporate, commercial and non-contentious IP matters in the sector. 

Charles Waddell is a well known corporate finance specialist in the sector. His primary focus is advising in the biotechnology and medtech sectors on equity raisings, mergers and acquisitions and other corporate transactions..  The team, which is ranked in the top tier of Life Sciences advisers by leading independent legal directories Chambers and Legal 500, has a strong client base of pharmaceutical, drug delivery, biotech and, medtech companies.

They arrive from the London office of Canadian firm Fasken Martineau and will bring the total number of lateral hires announced by Pinsent Masons in 2013 to seven.

David Ryan, Managing Partner of Pinsent Masons, says:

"We have started the year strongly, with significant hires into those areas where we see the greatest opportunity for growth domestically and internationally, and will continue to make investments in line with our sector-focused strategy.

"These appointments ensure that Pinsent Masons' offering in the Life Sciences sector is unrivalled, providing in depth expertise on business critical issues as well and the ability to deploy 'go to' partner specialists on all business as usual areas.We are therefore delighted that Paul and his colleagues are joining us.”

Key Contacts

Clare Tunstall

Clare Tunstall

Partner, Head of IP & Life sciences

View Profile

Latest press releases

Show me all press releases

Pinsent Masons launches online tool to spot future home-working related litigation for financial services firms

Multinational law firm Pinsent Masons has launched a new working-from home audit tool to help financial services organisations understand the hidden litigation and regulatory risks associated with staff increasingly working from home on a more permanent basis.

Pinsent Masons advises Seraphine Group PLC on its £150m main market IPO

Multinational law firm Pinsent Masons is advising Seraphine Group plc, an international digitally-led maternity and nursing wear, on its IPO and premium listing on the main market of the London Stock Exchange.

Pinsent Masons agrees MOU with Nepal International ADR Center

Multinational law firm Pinsent Masons has today signed a memorandum of understanding (MOU) with Nepal International ADR Center (NIAC), commencing an important collaborative relationship seeking to enhance NIAC’s international arbitration capabilities.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons unveils FY21 year end results

Multinational law firm Pinsent Masons has announced its FY21 year end results, reporting against last year’s metrics as the firm advances its strategy to become a purpose-led, professional services business with law at the core.

Pinsent Masons to cut absolute global carbon emissions by at least 50%

Multinational law firm Pinsent Masons has unveiled targets to cut absolute carbon emissions by a minimum of 50% by 2030, as it continues to reduce its environmental impact and support clients in tackling the climate crisis.

Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts